| abstract |
The present invention relates to the pyrazolopyrimidines and pyrazolotriazines of the formulas (1) and (2), or pharmaceutically acceptable salts thereof.n n n n n n n n n n n n n n n n n Surprisingly, these compounds have selective affinity for the 5-HT 6 receptor. Thus, they are of central nervous system diseases such as psychosis, schizophrenia, mood swings, depression, neurological diseases, memory disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease and Huntington's chorea. Suitable for treatment and prevention |